797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

• Joseph Markowitz,
• Siqing Fu,
• Gregory Daniels,
• Lyudmila Bazhenova,
• Nikhil Khushalani,
• Zeynep Eroglu,
• Andrew Brohl,
• Heather Yeckes-Rodin,
• Lori McCormick,
• Michael Kurman,
• Mireille Gillings,
• Gloria Lee

Affiliations

Joseph Markowitz

Aff2 Division of Medical Oncology 406C Starling Loving Hall 320 W 10th Ave 43210 Columbus OH USA

Siqing Fu

Aff3 grid.240145.60000000122914776University of Texas M.D. Anderson Cancer Center Houston TX USA

Gregory Daniels

3University of California, La Jolla, CA, USA

Lyudmila Bazhenova

Aff4 grid.266100.30000000121074242University of California San Diego CA USA

Nikhil Khushalani

Aff43 grid.468198.a0000000098915233H. Lee Moffitt Cancer Center Tampa FL USA

Zeynep Eroglu

Aff6 grid.468198.a0000000098915233Department of Cutaneous OncologyMoffitt Cancer Center 12902 USF Magnolia Drive 33612 Tampa FL USA

Andrew Brohl

4H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Heather Yeckes-Rodin

3Hem-Onc Associates of the Treasure Coast, Port St. Lucie, FL, USA

Lori McCormick

1Moffitt Cancer Center, Tampa, FL, USA

Michael Kurman

5HUYA Bioscience International, San Diego, CA, USA

Mireille Gillings

5HUYA Bioscience International, San Diego, CA, USA

Gloria Lee

5HUYA Bioscience International, San Diego, CA, USA